Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: A multicenter study

TACE in combination with systemic therapy shows improved survival benefit and manageable safety profiles compared to systemic therapy alone for HCC patients with HVTT/IVCTT. These findings provide preliminary evidence supporting the integration of TACE into first-line systemic therapy for this patient population. However, given the retrospective nature of this study, validation through prospective randomized controlled trials is warranted.

Authors

Institutions

Publication Details

Journal
International Journal of Surgery
Published
2025-12-08
DOI
https://doi.org/10.1097/js9.0000000000004144
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: A multicenter study

Jian-Jia Chen, Yang Weizhu, Guan‐Hui Zhou, Ming Huang et al.
International Journal of Surgery
Hepatocellular Carcinoma Treatment and Prognosis
article

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: A multicenter study

Jian-Jia Chen, Yang Weizhu, Guan‐Hui Zhou, Ming Huang, Chang Zhao, Jiansong Ji, Long-Wang Lin, Hong-Tao Hu, Zhicheng Jin, Hai‐Dong Zhu, Qian Chen, Weidong Wang, Aibing Xu, Zhou-Chao Hu, Xiaoli Zhu, Hai‐Bin Shi, Yun Zhou, Guohui Xu
article en

Abstract

TACE in combination with systemic therapy shows improved survival benefit and manageable safety profiles compared to systemic therapy alone for HCC patients with HVTT/IVCTT. These findings provide preliminary evidence supporting the integration of TACE into first-line systemic therapy for this patient population. However, given the retrospective nature of this study, validation through prospective randomized controlled trials is warranted.

International Journal of SurgeryVol. 112(3)
Fujian Medical University (CN), University of British Columbia (CA), Kunming Medical University (CN), Lishui University (CN), Zhengzhou University (CN), Soochow University (CN), Nantong Tumor Hospital (CN), Zhongda Hospital Southeast University (CN), Sichuan Cancer Hospital (CN), Zhoushan Hospital (CN), Henan Cancer Hospital (CN), Jiangsu Province Hospital (CN), First Affiliated Hospital of Soochow University (CN), Tumor Hospital of Guangxi Medical University (CN), Wuxi People's Hospital (CN), Union Hospital (CN), First Affiliated Hospital Zhejiang University (CN), Zhejiang University (CN), Nanjing Medical University (CN)
Openalex Percentile: Top 49%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.